Povidone
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Povidone: From Pharmaceutical Excipient to Congenital Ichthyosiform Erythroderma
One-Sentence Summary
Povidone (polyvinylpyrrolidone, PVP) is a pharmaceutical excipient used as a tablet binder, topical antiseptic base (e.g., povidone-iodine), and plasma volume expander, without a specific approved therapeutic indication of its own. The TxGNN model predicts a possible association with Congenital Ichthyosiform Erythroderma, but this prediction is currently supported only by a model score — no clinical trials and no literature are available.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved indication on record (used as excipient / topical antiseptic base) |
| Predicted New Indication | Congenital Ichthyosiform Erythroderma |
| TxGNN Prediction Score | 99.11% (rank 19,302) |
| Evidence Level | L5 |
| Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for povidone. Based on known information, povidone is a pharmaceutical excipient/carrier polymer — used clinically as a tablet binder, as the base matrix in topical antiseptics (e.g., povidone-iodine), and as a plasma substitute. It does not have a well-defined pharmacological target of its own, so its “efficacy” in prior uses is functional (formulation/delivery) rather than therapeutic.
Congenital ichthyosiform erythroderma is a genetic keratinization disorder (e.g., involving TGM1, ALOX12B mutations) affecting epidermal differentiation. There is no established mechanism linking povidone’s physicochemical properties (film-forming, moisture-retention, carrier function) to the keratinocyte differentiation pathways implicated in this disease. The high TxGNN score (0.99) most likely reflects an indirect graph association — for example, with topical povidone-iodine formulations used in dermatologic care — rather than a genuine pharmacological rationale. This prediction should be treated as a hypothesis-generating signal only, not as mechanistic evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Market Information
No marketed products or authorizations on record; povidone currently has no formal drug license entries in the dataset for this jurisdiction.
Safety Considerations
Please refer to the package insert for safety information.
(Key warnings, contraindications, and drug interaction data are currently unavailable — see Data Gap DG001, classified as Blocking, which prevents safety pre-screening.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence level is L5 (model prediction only) — there are no clinical trials, no literature, and no established mechanistic link supporting this indication. In addition, the drug is not currently marketed, and a Blocking data gap (TFDA label/warnings, DG001) prevents any safety pre-screening.
To proceed, the following is needed:
- TFDA package insert / warnings and contraindications (DG001, Blocking)
- Mechanism of action data from DrugBank (DG002, High)
- Preclinical or mechanistic studies linking povidone to keratinization pathways
- Any emerging clinical trial or literature evidence for this indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.